Johnson & Johnson (J&J) has lowered its 2026 profit outlook, citing costs from two recent biotech deals: the acquisition of Firefly Bio and a research partnership with Sail Biomedicines. The healthcare giant kept its revenue forecast steady, but the moves will weigh on earnings per share (EPS) in the near term.
What changed in the outlook
J&J now expects 2026 adjusted earnings of $10.96 to $11.11 per share, down from its previous range of $11.60 to $11.75. The company maintained its revenue forecast at $100.8 billion to $101.4 billion, signaling that the top-line business remains on track.
The profit reduction breaks down into two main pieces: the Firefly Bio acquisition is expected to cut 2026 adjusted EPS by about $0.46, while the Sail Biomedicines agreement will reduce it by another $0.18. These costs include upfront payments, research spending, and accounting charges tied to acquired intangible assets—common expenses when a company buys or partners with early-stage biotech firms.
Why J&J is spending on biotech deals
J&J has been actively reshaping its pharmaceutical pipeline through acquisitions and partnerships, especially in areas like oncology and immunology. Firefly Bio focuses on antibody-drug conjugates, a type of targeted cancer therapy that delivers drugs directly to tumor cells. Sail Biomedicines works on RNA-based medicines, a field that has gained attention for its potential to treat a wide range of diseases.
These deals reflect a broader strategy among large drugmakers to supplement internal research with external innovation. By buying or partnering with smaller biotechs, companies like J&J can gain access to promising technologies without waiting years to develop them from scratch. The trade-off is that these investments often depress near-term profits, as the costs hit the income statement before any new products generate revenue.
Other healthcare companies have taken similar approaches. For example, Regency Centers lifted its 2026 profit forecast recently, but that was driven by real estate rents, not biotech R&D. In contrast, J&J's move is a reminder that pharmaceutical earnings can be volatile when companies make big bets on unproven science.
What it means for investors
For everyday investors, the key takeaway is that J&J's revenue outlook remains solid, but the profit picture has become less certain. Adjusted EPS is a measure that strips out some one-time items, but the costs from these deals are real and will reduce the company's earnings power in 2026.
Investors should watch for updates on how Firefly Bio's and Sail Biomedicines' programs progress. If the technologies lead to successful drugs, the long-term payoff could outweigh the initial earnings hit. But if the deals fail to produce results, the profit drag may persist without a compensating benefit.
J&J's decision to keep its revenue forecast unchanged suggests that management sees the core business—selling existing drugs, medical devices, and consumer health products—as stable. The profit cut is entirely due to the new investments, not a deterioration in operations.
This type of situation is common in the pharmaceutical industry, where companies routinely trade short-term earnings for long-term growth. Starbucks recently lifted its outlook after a menu overhaul, but that was a consumer-facing turnaround, not a biotech gamble. J&J's story is different: it's about placing bets on science that may take years to pay off.
Broader context for the healthcare sector
Large drugmakers have been under pressure to find new growth drivers as patents on blockbuster drugs expire. J&J faces its own patent cliffs, particularly for its psoriasis drug Stelara, which lost patent protection in the U.S. in 2023. Acquisitions and partnerships are one way to fill the pipeline.
The biotech sector has seen a wave of dealmaking in recent years, as big pharma companies use their cash to buy promising assets at relatively attractive prices. The interest rate environment has made it cheaper for smaller biotechs to stay private, but large companies still find opportunities to acquire or partner with them.
J&J's move also comes amid a broader trend of healthcare companies adjusting their outlooks. Cognizant recently lifted its profit outlook on strong financial services revenue, but that was in the IT services space, not healthcare. For J&J, the profit cut is a deliberate choice to invest in future growth, not a sign of trouble.
What to watch next
Investors will likely focus on J&J's next earnings call for more details on the Firefly Bio and Sail Biomedicines deals, including timelines for clinical trials and potential regulatory milestones. The company's ability to integrate these assets and deliver on its long-term revenue targets will be key.
For now, the message is clear: J&J is willing to accept lower near-term profits to build a stronger pipeline. Whether that bet pays off will depend on the science—and on how well the company executes its strategy.
